肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

中国Castleman病诊断与治疗专家共识

2021-07-14 中国抗癌协会血液肿瘤专业委员会 中华血液学杂志 发表于上海

淋巴瘤Castleman病

Castleman病(Castleman disease, CD)又称巨大淋巴结病或血管滤泡性淋巴结增生症。近年来国内外对CD的发病机制、诊断和治疗的研究均取得了较大进展。

中文标题：

中国Castleman病诊断与治疗专家共识

发布机构：

中国抗癌协会血液肿瘤专业委员会

发布日期：

2021-07-14

简要介绍：

Castleman病(Castleman disease, CD)又称巨大淋巴结病或血管滤泡性淋巴结增生症。近年来国内外对CD的发病机制、诊断和治疗的研究均取得了较大进展。2018年CD入选国家卫健委发布的《第一批罕见病目录》。2021年中国Castleman病协作组成立。为了规范该病的诊断和治疗,国内相关专家制定了本共识。

相关资料下载：
[AttachmentFileName(sort=1, fileName=中国Castleman病诊断与治疗专家共识(2021年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=1e9e21c002259230, title=中国Castleman病诊断与治疗专家共识, enTitle=, guiderFrom=中华血液学杂志, authorId=0, author=, summary=Castleman病(Castleman disease, CD)又称巨大淋巴结病或血管滤泡性淋巴结增生症。近年来国内外对CD的发病机制、诊断和治疗的研究均取得了较大进展。, cover=https://img.medsci.cn/2021119/1636455790123_5579292.jpg, journalId=0, articlesId=null, associationId=1385, associationName=中国抗癌协会血液肿瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Wed Jul 14 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">Castleman病(Castleman disease, CD)又称巨大淋巴结病或血管滤泡性淋巴结增生症。近年来国内外对CD的发病机制、诊断和治疗的研究均取得了较大进展。2018年CD入选国家卫健委发布的《第一批罕见病目录》。2021年中国Castleman病协作组成立。为了规范该病的诊断和治疗,国内相关专家制定了本共识。</span></p>, tagList=[TagDto(tagId=412, tagName=淋巴瘤), TagDto(tagId=80135, tagName=Castleman病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100), CategoryDto(categoryId=21105, categoryName= 2024年第十七届国际罕见病日活动, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=80135, guiderKeyword=Castleman病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3406, appHits=126, showAppHits=0, pcHits=863, showPcHits=3280, likes=0, shares=9, comments=6, approvalStatus=1, publishedTime=Tue Nov 16 23:57:33 CST 2021, publishedTimeString=2021-07-14, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Nov 09 22:13:22 CST 2021, updatedBy=92910, updatedName=rayms, updatedTime=Thu Feb 29 17:14:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国Castleman病诊断与治疗专家共识(2021年版).pdf)])
中国Castleman病诊断与治疗专家共识(2021年版).pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1077978, encodeId=fe2410e79781c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Dec 08 07:56:07 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070667, encodeId=e9ee10e0667e2, content=学习了！有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02039064, createdName=予沫, createdTime=Tue Nov 16 09:12:28 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069063, encodeId=32b4106906332, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Wed Nov 10 20:17:54 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068844, encodeId=c5791068844ec, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Nov 10 06:48:24 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
    2021-12-08 最后一直多巴胺

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1077978, encodeId=fe2410e79781c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Dec 08 07:56:07 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070667, encodeId=e9ee10e0667e2, content=学习了！有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02039064, createdName=予沫, createdTime=Tue Nov 16 09:12:28 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069063, encodeId=32b4106906332, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Wed Nov 10 20:17:54 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068844, encodeId=c5791068844ec, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Nov 10 06:48:24 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
    2021-11-16 予沫

    学习了！有帮助

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1077978, encodeId=fe2410e79781c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Dec 08 07:56:07 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070667, encodeId=e9ee10e0667e2, content=学习了！有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02039064, createdName=予沫, createdTime=Tue Nov 16 09:12:28 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069063, encodeId=32b4106906332, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Wed Nov 10 20:17:54 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068844, encodeId=c5791068844ec, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Nov 10 06:48:24 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
    2021-11-10 ms9000000410256940

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1077978, encodeId=fe2410e79781c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3ed5511789, createdName=最后一直多巴胺, createdTime=Wed Dec 08 07:56:07 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070667, encodeId=e9ee10e0667e2, content=学习了！有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74b02039064, createdName=予沫, createdTime=Tue Nov 16 09:12:28 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069063, encodeId=32b4106906332, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befe5704258, createdName=ms9000000410256940, createdTime=Wed Nov 10 20:17:54 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068844, encodeId=c5791068844ec, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Nov 10 06:48:24 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
    2021-11-10 微探

    学习学习

    0

相关指南

中国淋巴瘤治疗指南(2021年版)

中国抗癌协会淋巴瘤专业委员会 · 2021-07-03

澳大利亚和新西兰关于 COVID-19 大流行期间淋巴瘤、慢性淋巴细胞白血病和骨髓瘤管理的共识声明 2020

暂未更新 · 2020-07-15

2021 共识建议：玻璃体视网膜淋巴瘤的诊断

国外肿瘤科相关专家小组（统称） · 2021-05-19

淋巴瘤 18F-FDG PET/CT及PET/MR显像临床应用指南（2021版）

中华医学会核医学分会(CSNM,Chinese Society of Nuclear Medicine) · 2021-03-28

淋巴瘤自体造血干细胞动员和采集中国专家共识（2020年版）

中华医学会血液学分会(CMA,CHINESE MEDICAL ASSOCIATION) · 2020-12-30

癌症免疫疗法协会（SITC）关于免疫疗法治疗淋巴瘤的临床实践指南2020

肿瘤免疫治疗学会(SITC,Society for Immunotherapy of Cancer) · 2020-12-16

拓展阅读

2020 国际循证共识：单中心型Castleman病的诊断和治疗指南

国外血液科相关专家小组 · 2020-12-06

特发性多中心 Castleman 病管理中未满足的临床需求：来自特设专家小组的基于共识的立场文件

欧洲血液学协会(EHA,European Haematology Association) · 2023-06-02